RxDoctor Payments Data

David Clarke, MD

Family Medicine · Canyon, TXNPI 1245241231

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 88 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$332
  • AbbVie$164
  • AstraZeneca$150
  • UCB, Inc.$150
  • Pfizer$103
  • Amgen$83
  • plus $510 from 18 others

What the payments were for

  • Food & beverage$1,492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,492 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$311,261
Medicare patients
541
Services billed
10,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$98,095
MounjaroTirzepatide72$71,929
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$65,466
JardianceEmpagliflozin56$46,809
RybelsusSemaglutide24$38,798
FarxigaDapagliflozin Propanediol30$35,851
EliquisApixaban47$27,072
Tresiba Flextouch U-200Insulin Degludec16$14,403
Repatha SyringeEvolocumab18$9,332
MovantikNaloxegol Oxalate11$4,857
LantusInsulin Glargine,hum.Rec.Anlog25$4,349
Np ThyroidThyroid,pork61$3,997
Levothyroxine Sodium371$3,732
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,446
Liothyronine Sodium88$3,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$63$136,892113 claims
Lilly USA, LLCMounjaro$15$71,92972 claims
GSKTrelegy Ellipta$332$65,46679 claims
Boehringer IngelheimJardiance$19$46,80956 claims
AstraZenecaFarxiga$150$35,85130 claims
PfizerEliquis$103$27,07247 claims
Sanofi-aventis U.S. LLCLantus$13$4,34925 claims
AbbVieSynthroid, Armour Thyroid$164$3,24255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Canyon

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →